United States Patent 7,812,163 (Hatching Inhibition via Metal Chelating Agents) Patent Scope, Claim Coverage, and US Landscape
United States Patent 7,812,163 claims topical compositions containing a defined class of metal chelators (formula (Ia), including specific 2,2′-dipyridyl isomers such as 5,5′-dimethyl-2,2′-dipyridyl) for inhibiting hatching of ectoparasite eggs, plus dependent claim pathways into specific ectoparasite taxa, host types, dosage forms, and combination with a second ectoparasiticide. The estate scope is claim-driven around: (i) the chelator structure and salt forms, (ii) topical exposure/contact with eggs, and (iii) the functional outcome “inhibiting hatching.” Below is a structured breakdown of claim coverage and the practical patent landscape implications for infringement, design-around, and licensing.
What exactly does US Patent 7,812,163 claim for inhibiting ectoparasite egg hatching?
Independent claim 1: core infringement hook
Claim 1 is a method of inhibiting hatching of an ectoparasite egg by exposing the egg to a topical composition containing at least one metal chelating agent that is a compound of formula (Ia) (or a pharmaceutically/veterinary/agriculturally acceptable salt).
The chelator is structurally constrained:
- Formula (Ia) scaffold definition
- X is one of: covalent bond, CH2—Z—CH2, or —Z—
- R1 and R1′ are independently: hydrogen or C1–3 alkyl
- At least one of: R2, R2′, R3, R3′, R4, R4′ is methyl
- Remaining R2/R2′/R3/R3′/R4/R4′ are independently hydrogen or C1–3 alkyl
- Z is: covalent bond, —NH—, —O—, —S—, —C(O)—, —C(S)—
- Salt forms are included.
Functional requirement: “inhibiting hatching” requires the egg is exposed topically to the composition; the outcome is hatching inhibition, not necessarily adult mortality.
How broad is “topical composition” in claim 1?
Claim 1 itself does not list dosage forms. Dependent claims 13–16 do. Still, “topical composition” combined with “exposing the ectoparasite egg to” effectively covers formulations applied to a surface where eggs are located (host surface, plant surface, etc.), including aqueous and non-aqueous carrier systems as long as topical contact with eggs occurs.
Independent claim set shape: method coverage not just composition
US 7,812,163 is framed as methods, not merely “a composition comprising X.” That matters for infringement because method claim enforcement often targets use and application activity (label instructions, commercial use practices) rather than composition manufacture alone.
Which chelators are explicitly covered by US 7,812,163 formula (Ia)?
Dependent claim 3: enumerated embodiments
Claim 3 narrows formula (Ia) to specified examples:
- 6,6′-dimethyl-2,2′-dipyridyl
- 5,5′-dimethyl-2,2′-dipyridyl
- 4,4′-dimethyl-2,2′-dipyridyl
- or acceptable salts.
These listed embodiments sit inside formula (Ia). Practically, they give enforcement clarity around these three isomeric dimethyl dipyridyl chelators.
Dependent claim 17 reinforces a particular isomer
Your excerpt includes claim 17: “composition 5,5′-dimethyl-2,2′-dipyridyl” for claims 13–16 (formulation/dosage forms scope). That is a second anchor for that specific chelator.
Practical claim consequence
To avoid claim 1, a product generally must do at least one of:
- Use a metal chelator outside formula (Ia) (structural design-around), or
- Avoid topical exposure/contact with ectoparasite eggs (route avoidance), or
- Avoid the claimed functional objective of inhibiting hatching (hardest to manage because function can be inferred from label claims and test results), or
- Avoid covered salt inclusion (rare, since salts are typically encompassed).
Do claims cover all ectoparasites or only a defined taxonomy?
Dependent claims 4 and 8: broad order-level coverage
Claim 4 (dependent on claim 1) specifies ectoparasite species laid by hosts in orders including:
- Lepidoptera, Hemiptera, Orthoptera, Psocoptera, Hymenoptera, Isoptera, Coleoptera, Dictyoptera, Thysanoptera, Homoptera, Diptera, Anaplura, Malophaga, Siphonaptera, Arachnida, Phthiraptera.
Claim 8 (dependent on claim 6) mirrors this order list.
This gives claim coverage across major pest categories (insects and mites including lice-associated taxa).
Dependent claims 5 and 9: specific species list (heavy infringement relevance)
Claim 5 (dependent on claim 4) and claim 9 (dependent on claim 8) list named species, including:
- Multiple Lepidoptera species (Helicoverpa spp, Plutella xylostella, etc.)
- Lice and mites, including:
- Bovicola ovis, Bovicola bovis
- Haemotopinus eurysternus
- Linognathus vituli
- Solenoptes scabiei suis
- Sarcoptes scabiei bovis, Psoroptes ovis
- Pthirus pubis
- Pediculus humanus capitis and Pediculus humanus humanus
- Dermatophgoides spp.
- Sarcoptes scabiei var. humani
These species lists are important in litigation because they provide concrete target organisms tied to label usage scenarios and likely test data.
Dependent claim 10: explicit lice infestation framing
Claim 10 (dependent on claim 6) states the infestation is “a lice infestation.” That simplifies argument that lice treatment scenarios fall within the method’s functional target of egg hatching inhibition.
Does the patent cover humans, animals, plants, or all hosts?
Dependent claims 6–7 and 4/8-style structure
Claim 6 is a method of treating ectoparasite infestation in a host by:
- Topically applying to the host
- So the ectoparasite egg on the host comes into topical contact with an effective amount of the chelator (formula (Ia)).
Claim 7 expands host type:
- “The host is a plant, an animal or a human.”
So US 7,812,163 is not limited to companion animals or agriculture; it expressly covers human scalp treatment scenarios (further addressed in claims 15–16).
What product formats are covered: dip, spray, aerosol, shampoo, mousse, lotion, dust?
Dependent claims 13–16: direct topical application dosage forms
Claim 13 (dependent on claim 1) and Claim 14 (dependent on claim 6) include formulation forms selected from:
- dip, spray, aerosol, shampoo, mousse, emulsion, solution, cream, dust, lotion.
Claims 15 and 16 add the human head lice condition:
- Ectoparasite egg is human head lice eggs
- Composition is formulated for topical application to the human scalp
- Form is selected from the same set (dip/spray/aerosol/shampoo/mousse/emulsion/solution/cream/dust/lotion).
Claim 17 ties a specific embodiment:
- For claims 13–16, the composition is 5,5′-dimethyl-2,2′-dipyridyl.
Practical consequence for infringement
A competitor must avoid the combination of:
- applying the chelator-formulated product topically to scalp or other host surfaces where eggs reside, and
- using a covered chelator within formula (Ia), and
- achieving egg hatching inhibition.
Since the claims list many common delivery systems, “we used a different presentation” is unlikely to be a clean design-around if the carrier is still topical.
Can the patent be enforced against combination products with other ectoparasiticides?
Dependent claims 11–12: co-application and nymph/adult coverage
Claim 11 (dependent on claim 6) states the metal chelating agent can be applied simultaneously, separately or sequentially with a second ectoparasiticide.
Claim 12 specifies the second ectoparasiticide controls nymphs and/or adult ectoparasites.
Litigation relevance
This materially reduces a typical design-around path. Many ectoparasiticide products combine adulticidal activity with ovicidal/eggs inhibition claims. Here, the patent anticipates combination regimens where the chelator addresses egg hatching and another active addresses live stages.
What is the operational claim scope: “method” vs “composition” and what must be practiced?
Elements that usually drive infringement analysis
Across claims 1 and 6, infringement practice requires:
- Topical composition (or composition used topically) containing metal chelating agent of formula (Ia) (or salts)
- Ectoparasite egg exposure/contact occurs due to application to the host or surface
- The chelator is used at an effective amount for claim 6
- The claimed functional result is inhibiting hatching (claim 1)
Evidence types that tend to matter
- Product labeling and instructions (what eggs are targeted, lice vs other ectoparasites, scalp vs other host)
- Application method (topical contact with eggs)
- Composition chemistry proof (formula (Ia) match)
- Bioassay data demonstrating hatching inhibition
How strong is the patent estate around chelator structure vs downstream formulation?
Claim dependency architecture
- Claims 1 and 6 anchor broadly on the functional objective + topical exposure + formula (Ia).
- Dependent claims 3, 4–5, 7–10, 13–17, and 11–12 layer in narrower species taxonomy, host type, dosage forms, and combination regimens.
This architecture typically creates two enforcement tiers:
- Core enforcement: formula (Ia) chelator used topically to inhibit egg hatching.
- Secondary enforcement: human scalp/lice, listed species, and common dosage forms provide easier factual mapping to commercial products.
Design-around pressure points
The most direct design-around is chemistry: use a chelator not within formula (Ia). Avoiding the “methyl-substituted dipyridyl-like” structure implied by R constraints (with at least one methyl among R2/R2′/R3/R3′/R4/R4′, Z defined) is the primary freedom window.
A carrier-only change is unlikely to avoid because claims include many topical formats.
What does this patent imply for a competitor developing generic or follow-on ectoparasitic treatments?
Generic entry risks for a “chelator for eggs” mechanism
Because the claim covers methods of inhibition of egg hatching, a generic risk profile turns on:
- whether the generic product uses the same or equivalent chelator isomer(s) within formula (Ia)
- whether the product is used for the same egg-stage hatching inhibition purpose
- whether the label claims or real-world use include scalp/host topical application where eggs are present
If the chelator is changed outside formula (Ia), the method claims should not read on the alternate chemistry even if the function is similar.
Product positioning risk
Even if a competitor positions the chelator as an “egg/viability” agent, if its mechanism is functionally to inhibit hatching and it is applied topically to eggs on the host, claim scope can be implicated via claim 1’s functional language.
Orange Book status, FDA regulatory posture, and Paragraph IV relevance
No drug-specific Orange Book entries, FDA application numbers, or Orange Book-listed patents are provided in the prompt. Without a named drug product or the Orange Book listing, it is not possible to map US 7,812,163 to:
- a specific reference listed drug (RLD),
- an NDA/BLA,
- a regulatory exclusivity expiration,
- or to any Paragraph IV litigation.
Accordingly, the Paragraph IV and exclusivity timing analysis cannot be completed from the supplied information.
What could be the closest prior art or related patent space around metal chelators and ectoparasites?
The claim is explicitly about metal chelating agents, including dimethyl 2,2′-dipyridyl derivatives, used topically to inhibit egg hatching across a wide range of ectoparasite orders. In the broader field, this positions the invention at the intersection of:
- metal-chelator chemistry,
- ovicidal/eggs-stage control,
- and topical delivery for lice and other ectoparasites.
However, no prior-art patent numbers, assignees, or citation lists are provided in the prompt. As a result, a complete “how many patents cover this” or “who owns the estate” competitive landscape cannot be generated accurately.
Patent claim coverage matrix for infringement scenario mapping
| Scenario |
Claim anchor |
What must be true |
Likely coverage under US 7,812,163 |
| Topical product with formula (Ia) chelator applied to host where ectoparasite eggs exist; egg hatching inhibited |
Claim 1 |
Ectoparasite egg exposed topically to formula (Ia) chelator |
Yes, core scope |
| Human head lice eggs on scalp treated with formula (Ia) chelator in shampoo/cream/spray |
Claims 6, 15–16 (and 17 if 5,5′-dimethyl-2,2′-dipyridyl) |
Scalp topical application + lice egg hatching inhibition + covered chelator |
Yes, high mapping |
| Treatment for lice with chelator plus an adulticide/larvicide |
Claims 11–12 |
Co- or sequential application with second ectoparasiticide; second controls nymphs/adults |
Yes |
| Agricultural insect egg hatching inhibition using same chelator |
Claims 4–5 |
Egg laid by listed orders/species + topical exposure + covered chelator |
Yes |
| Switching delivery vehicle only (lotion to dust) |
Claims 13–14 |
Still topical application and egg contact with covered chelator |
Likely still Yes |
| Using a different chelator not in formula (Ia) |
Claim 1/6 chelator limitation |
Chemistry no longer meets formula (Ia) |
Likely avoid |
| Systemic (oral/injection) treatment that does not rely on topical contact with eggs |
Claim element “topical” + egg contact |
No topical exposure of eggs |
Likely avoid |
Key Takeaways
- US 7,812,163 is anchored on topically exposing ectoparasite eggs to a defined metal chelator class (formula (Ia)) to inhibit hatching.
- Explicit chelator embodiments include 6,6′-, 5,5′-, and 4,4′-dimethyl-2,2′-dipyridyl, with 5,5′-dimethyl-2,2′-dipyridyl specifically tied to several topical dosage forms.
- The estate scope expands to human scalp head lice and many topical formats (dip/spray/aerosol/shampoo/mousse/emulsion/cream/dust/lotion).
- The claims also cover combination regimens where the chelator is used alongside a second ectoparasiticide controlling nymphs/adults.
- The most reliable design-around is chemical (using a metal chelator outside formula (Ia)). Carrier changes alone are unlikely to avoid.
FAQs
- What chelator structural differences are most likely to avoid infringement of US 7,812,163 formula (Ia)?
- If a product claims “prevents egg development” but does not explicitly say “inhibiting hatching,” how do the method claims apply?
- Do the dosage form lists in claims 13–16 broaden coverage to both consumer and professional lice treatments?
- How does the co-application language in claims 11–12 affect product combinations with adulticides?
- For agricultural pests, does the order/species language in claims 4–5 create discrete infringement risk bands?
References
- United States Patent 7,812,163. (Claim text provided in prompt).
